Mechanistically, ADRB2 can activate the adenylyl cyclase/cAMP/CREB pathway in NSCLC [17], consistent with Bernhard et al.’s revelation that the ADRB2/CREB and NGF-BDNF/Trk pathways are promising targets for pancreatic cancer treatment [18]. The gene discussed is CREB1; the disease is pancreatic neoplasm.